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Abstract 
 
Background  
Cannabis usage is increasing with its widespread legalization. Cannabis use by mothers during 
lactation transfers active cannabinoids to the developing offspring during this critical period and 
alters postnatal neurodevelopment. A key neurodevelopmental landmark is the excitatory to 
inhibitory GABA switch caused by reciprocal changes in expression ratios of the K+/Cl-transporters 
KCC2 and NKCC1. 
 
Methods   
Rat dams were treated with THC or a synthetic cannabinoid during the first 10 days of postnatal 
development and experiments were then conducted in the offspring exposed to these drugs via 
lactation. The network influence of GABA transmission was analyzed using cell-attached 
recordings. KCC2 and NKCC1 levels were determined using Western blot and qPCR analyses. USV 
and homing behavioral experiments were carried out at relevant time-points. 
 
Results  
Treating rat dams with cannabinoids during early lactation retards transcriptional upregulation 
and expression of KCC2, thereby delaying the GABA switch in pups of both sexes. This perturbed 
trajectory was corrected by the NKCC1 antagonist bumetanide and accompanied by alterations in 
ultrasonic vocalization without changes in homing behavior. Neurobehavioral deficits were 
prevented by CB1R antagonism during maternal exposure, showing that CB1R underlie the 
cannabinoid-induced alterations. 
 
Conclusions  
These results reveal how perinatal cannabinoid exposure retards an early milestone of 
development, delaying the trajectory of GABA’s polarity transition and altering early-life 
communication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Cannabis is the most widely used illicit drug in the world with increasing use in Western nations 
(1). Its actions are primarily attributed to ∆9-tetrahydrocannabinol (THC), which acts on 
cannabinoid receptors (CB1R and CB2R), who together with naturally occurring endocannabinoids 
(eCBs) and their synthesizing/degrading enzymes, comprise the endogenous cannabinoid system 
(ECS; 2). Cannabis consumption during pregnancy ranges from 1-6% (3, 4) and will likely rise with 
widespread decriminalization and legalization. Public perception categorizes cannabis usage 
during pregnancy as low-risk (5). Nonetheless, consequences of infant exposure to cannabinoids 
remain poorly researched.  
 
The role of the ECS during development is well-established in animals (6, 7) and humans (8–10). 
Importantly, consumption of cannabis results in significant quantities of THC and active 
metabolites in breastmilk (11–13), which transfer to offspring in both humans (14) and animals 
(15, 16). Additionally, THC exposure has adverse impacts on fetal and perinatal 
neurodevelopment (17–19), with significant consequences throughout life (7, 20, 21). 
Furthermore, the ECS plays a crucial role in prefrontal cortex development (PFC; 22), a cognitive 
hub whose developmental perturbation has been linked to a variety of maturational deficits (23–
25).    
The PFC is the most highly evolved brain region (2, 24), participating in behaviors from working 
memory and emotion to cognitive flexibility (26, 27). The ECS is a modulatory neurotransmitter 
system in the PFC (28), highly concentrated at interneuron synapses (10, 29) and more prevalent 
in deep than superficial layers (30, 31). Importantly, eCBs serve a critical function in the 
developmental trajectory of GABAergic interneurons (32). Consequently, ECS perturbations 
during neonatal development have lasting effects on GABAergic transmission (33). 
 
While GABA is the primary adult inhibitory neurotransmitter, in immature brains it exhibits 
excitatory influence due to high intracellular Cl- caused by low levels of the KCC2 chloride 
transporter (34). Increasing KCC2 expression and declining NKCC1, subsequently decrease 
intracellular Cl- (34–37), mediating the inhibitory transition of GABA. Aberrations in this 
transition’s timing are linked with disorders including autism, Down syndrome, Fragile X and 
schizophrenia (38–42). Its timing differs between brain regions: from embryonic day 15 in 
hippocampus to postnatal day (P) 15 in neocortex (43). The development of PFC GABA synapses is 
maximal between P10-15 (44, 45), though the functional valence of these sites has not been 
investigated. 
 
The sparse data of the consequences of ECS perturbation during the postnatal period on 
GABAergic function suggest significant, lasting impacts (46). While it is known that cannabis 
exposure during PFC development has profound consequences (47), the mechanistic 
underpinnings remain largely unexplored. Here, we investigated the postnatal impact of 
cannabinoids via maternal exposure to assess potential risks associated with cannabis use during 
this period. 
 
 
 
 
 
 
 
 
 
Methods 
 
Further information and requests for resources/reagents should be directed to the Lead Contact, 
Olivier J.J. Manzoni (olivier.manzoni@inserm.fr). 
 
Animals  
Animals were treated in compliance with the European Communities Council Directive 
(86/609/EEC) and the United States NIH Guide for the Care and Use of Laboratory Animals. All 
rats were group-housed with 12h light/dark cycles with ad libitum access to food and water. All 
behavioral, biochemical and synaptic plasticity experiments were performed on male and female 
RjHan:wi-Wistar rats (P09-21) from pregnant females obtained from Janvier Labs. Pregnant dams 
arrived at E15 and remained undisturbed until delivery. Newborn litters found before 05:00p.m. 
were considered to be born that day (P0). Male and female electrophysiological and biochemical 
results exhibited no difference; thus data were pooled (Tables 1-2 for details).   
 
Maternal behavior was assessed by quantifying time in the nest and nursing time/type (Table 3). 
Observations were made twice daily (10h/16h) during 1 of every 5 minutes for 20 minutes. No 
treatments impacted time in the nest (Table 3; F3,4=1.129, p=0.4374, one-way ANOVA) or nursing 
(F3,44=5.398, p>0.9999, one-way ANOVA). 
 
Pups from WIN- or THC-treated dams exhibited slower growth (significantly lower average 
weights) from P07-10 (Table 4; F3,5=15.63, p=0.0057). In line with electrophysiological and 
biochemical data, co-administration of AM-251 prevented the reduced weight gains in pups by 
P10 (P=0.0970 compared to Sham P10, Tukey’s multiple comparisons test). 
 
Drug treatments  
Dams were injected daily sub-cutaneously (s.c.) from P01-10 with the synthetic cannabimimetic 
WIN55,212-2 (WIN; 0.5mg/kg/day) alone or with AM-251 (0.5mg/kg/day), or with ∆9-
Tetrahydrocannabinol (THC; 2mg/kg/day). WIN55,212-2, THC or AM-251 were suspended in 
1:1:18 DMSO, cremophor and saline, and injected at 1ml/kg. Control dams (Sham) received 
vehicle. Bumetanide (in 0.1% DMSO, 99.9% saline) was injected twice daily (0.2mg/kg/injection, 
10µl/g; 09:00a.m. and 05:00p.m.) from P01-15. 
 
Electrophysiology  
Coronal slices containing the prelimbic area of the medial prefrontal cortex (mPFC) were 
prepared as previously described (Lafourcade et al., 2007). Details of slice-preparation and 
acquisition are in Supplemental Methods. 
 
Spontaneous Spiking Activity  
Spontaneous spiking activity was recorded in cell-attached configuration with a patch pipette 
filled with ACSF. A >500 MOhm seal was obtained in current-clamp configuration before 
recording in I=D0 mode. Data were filtered at 2 kHz and digitized at 10 kHz. Activity was analyzed 
in Clampfit 10.5 (Molecular Devices) threshold detection with a trigger threshold of 
 
 
 
 
 
 
 
 
>2x SD of baseline noise. Mean spike activity was calculated as an average of spikes per minute 
over a 10-minute baseline period. For drug-effects, means represent an average of spikes/min 
over a 10-minute period following >5 minutes of bath perfusion. 
 
Single channel and whole-cell patch-clamp recordings 
Single-channel chloride reversal potential (GABArev) recordings were obtained in cell-attached 
configuration with a patch pipette containing an internal solution (detailed in Supplemental 
Methods). A >500 MOhm seal was obtained in current-clamp configuration before recording 
activity at imposed voltages (-100mV to +40mV). Data were filtered at 1kHz and digitized at 5kHz. 
Channel openings were analyzed in Clampfit 10.5 (Molecular Devices). Current magnitudes were 
obtained from >10 openings per holding potential. GABArev was then calculated using the unitary 
chord conductance (γ) wherein γ = IA – IB/∆V (IA and IB ,current values with opposite polarity 
closest to the reversal potential) as previously described (48). Following channel recordings, 
membrane seals were broken and resting membrane potentials (Em) were confirmed in whole-
cell configuration within ~1min to avoid cell dialysis. Imposed values are relative to Vpipette 
zeroed in cell-attached mode and are thus a function of Em.  
 
Western-blots  
Brains were harvested and snap frozen in isobutane on dry ice and stored at -80C. A brain matrix 
(Braintree Scientific #BS-SS 605C) at -20C was used to prepare 1mm coronal sections. Brain 
regions were harvested on a dry ice-chilled glass plate. mPFCs were split at the midline and 
processed for either Western blot analysis or qRT-PCR. For Westerns, samples were homogenized 
in RIPA buffer (50mM Tris, pH8.0, 150mM NaCl, 1% Tx-100, 0.1% SDS, 0.5% CHAPS, 1x HALT 
protease and phosphatase inhibitor (Thermo Fisher Scientific, #78440)) and centrifuged 
(10,000xg, 10 minutes, 4oC). Supernatants were collected and mixed with 4X sample buffer and 
incubated (10 minutes at 65oC) and run on 4-12% NuPage gels (Thermo Fisher Scientific, 
#NP0323BOX). Following protein transfer, blots were stained (Revert Total Protein stain, Li-Cor, # 
926-11011), scanned for total protein and blocked in Li-Cor Blocking Buffer (Li-Cor Bioscience 
#927-40000; 60 minutes, 22oC). They were then incubated with either rabbit or mouse anti-KCC2 
or rabbit anti-NKCC1 diluted in a mixture of Li-Cor Blocking Buffer and 1XPBS (1:1). Blots were re-
probed for protein content using rabbit anti-GAPDH. Blots were incubated with primary 
antibodies overnight at 4oC. Next, blots were washed (4x15 minutes, 22oC) in TBST (20 mM Tris, 
pH 7.5, 150 mM NaCl, 0.05% Tween 20), then incubated in the buffer above containing Li-Cor 
donkey anti-rabbit IR680, donkey anti-rabbit IR800, donkey anti-mouse IR680 or donkey anti-
mouse IR800 antibodies (1 hour, 22oC). Finally, blots were washed as above and scanned on a Li-
Cor Odyssey near-IR imager. Apparent molecular weights were determined using either 
Benchmark (Thermo Fisher Scientific, #10748-010) or Chameleon (Li-Cor, #928-60000). Band 
densities were calculated using FIJI software. GAPDH staining and total protein over development 
and treatments were highly correlated. Bands corresponding to KCC2 and NKCC1 were 
normalized to GAPDH density. 
 
qRT-PCR 
 
 
 
 
 
 
 
 
 
 
qRT-PCR was performed on mPFC harvested as above following published procedures (20) 
Primers and probes described in the Key Resources table. Duplicates were run for each sample, 
and relative gene expression was determined using the double delta Ct method. 
 
Ultrasonic vocalizations  
USV induced by maternal isolation were recorded from male and female rats at P09 and P15 as 
described (49–51). Offspring were left undisturbed in homecages with their biological dams in the 
test room for habituation (30 minutes). Each pup (2-5 per litter) was tested individually in 
arbitrary order. USV were recorded over a 3-minute period in a sound attenuating isolation box 
(37x21x14cm) in another room and equipped with one white-light LED (30 lux). USV were 
recorded using an ultrasound microphone (Ultravox Noldus) 20 cm above the floor and 
connected via the Ultravox device (Noldus, Netherlands). Recordings were conducted from 8:00-
11:00 a.m. USV were scored for total number of calls and mean dominant frequency. As USV can 
be influenced by pups’ body temperature (52), box temperature was controlled over the test 
(352ºC).    
Homing behavior  
Homing behavior was tested as previously described (53). P10 and P13 pups of both sexes (2-
5/litter) were separated from their mother and placed on a heating pad at 352C. Pups were 
individually placed into a Plexiglas box (37x21x14cm) with 1/3:2/3 home-cage to fresh bedding. 
Pups were placed at the clean-bedding side and video recorded (4min). Homing performance was 
scored for latency to reach the home-cage litter, total time spent in the nest-litter area and 
number of crossings. Animals failing to reach the nest were eliminated from analysis. 
 
Quantification and statistical analysis  
Analyses were conducted using Microsoft Excel 2016 (Redmond, WA) and GraphPad Prism 7 (La 
Jolla, CA), with significance of 0.05. N values are presented as individual cell or animal (indicated 
in figure legends). Error bars indicate SEM. Significance was assessed by one-way or two-way 
analysis of variance (ANOVA; followed by Tukey’s multiple comparisons post hoc analyses), 
Mann-Whitney U test or Student's t-test. Grubb’s test (alpha level 0.05) was applied to all 
datasets to identify outliers which were subsequently excluded from datasets. Statistical details 
for each experiment are in corresponding figure legends. 
 
Results 
 
No differences were found between sexes throughout this study (Tables 1-2, Supplementary 
Tables 1-2). Thus, all data were pooled. 
 
In accord with international ethical guidelines to reduce animals used and their 
treatment/manipulations, once a lack of difference in outcomes in WIN- or THC-expose pups was 
established (Figures 1, 6), further experiments were carried out only with WIN. All experiments 
were repeated with a minimum of 2 litters. 
 
 
 
 
 
 
 
 
 
 
In the prefrontal cortex, GABA transitions from an excitatory to inhibitory neurotransmitter 
between P10 and P15 
 
While the developmental GABA trajectory has been characterized in several brain regions (35, 36, 
54, 55), it is unknown if it occurs in the medial prefrontal cortex (mPFC). To establish the 
existence and timing of GABA’s transition in rat mPFC, we used cell-attached recordings in slices 
containing layer 5 pyramidal neurons to observe spontaneous cell spiking activity before and after 
the application of either the GABAR antagonist picrotoxin (PTX) or positive allosteric modulator 
isoguavacine (ISO) as described (36, 44, 56).  
 
At P09-P10, application of PTX significantly decreased spike frequency (Figure 1a,c). Conversely, 
ISO significantly increased (Figure 1D,F) spike activity. These results are compatible with the idea 
that GABA serves as an excitatory neurotransmitter at P09-10. Conversely, cells recorded 
between P15-P16 exhibited increased spiking activity following PTX application (Figure 1a,c), 
while ISO significantly attenuated (Figure 1D,F) spike frequency. Similarly, at P20 PTX significantly 
increased spike frequency (Figure 1A,C) while ISO decreased spike frequency (Figure 1D,F). Thus, 
at or after P15, GABA-A receptor activation exerts an inhibitory influence on mPFC networks, 
indicating that GABA undergoes a functional “switch” from excitation to inhibition between P10 
and P15 which is sustained at P20. Thus, the mPFC GABA switch occurs at a similar time as in 
other brain regions (36). 
 
Perintal WIN or TCH delays the GABA “switch” 
 
Endocannabinoid signaling during early development, including the first postnatal weeks (57, 6), 
mediates GABA neuron connectivity (29). Therefore, we investigated the developmental 
consequences of cannabinoid exposure on GABA’s mPFC trajectory. Dams were treated with 
either the cannabimimetic CB1/2R agonist WIN 55,212-2 (WIN; 0.5mg/kg s.c.) or the principle 
psychoactive component of cannabis, ∆9-THC (THC; 2mg/kg, s.c.) from P01-P10. Cell-attached 
recordings were then performed as above from cannabinoid-treated progeny at three time points 
(Figure 1B-C, E-F). 
 
At P09-10, PTX significantly reduced spike frequency in slices obtained from pups exposed to 
either WIN or THC (Figure 1B-C), while application of ISO significantly increased spike frequency in 
both groups (Figure 1E-F). At P15-16, the effects of both drugs on spike frequency remained 
consistent PTX still attenuated spike frequency in slices obtained from WIN- or THC-exposed 
progeny (Figure 1B-C, E-F). Thus, in marked contrast to Shams, GABA remains excitatory at P15-
P16 in pups perinatally exposed to cannabinoids. 
 
Considering the delayed GABA switch in a number of disorders (58, 59, 40, 41) as well following 
alterations to maternal health (60) or behavior (61), we performed recordings on slices from WIN- 
or THC-exposed pups at P20-21 to ascertain whether the GABA switch had occurred at this age. 
P20-21 PTX application increased, while ISO application decreased spike frequency in slices from 
WIN- or THC-exposed pups (Figure 1B-C, E-F). Together with previous results, these findings 
indicate that in cannabinoid-exposed pups, GABA’s transition from excitatory to 
 
 
 
 
 
 
 
 
inhibitory is delayed, rather than absent. Importantly, co-administration of the CB1R antagonist 
AM-251 with WIN prevented this delay, indicating a CB1R-dependent locus of effect 
(Supplementary Figure 1). 
 
The GABA “switch” is correlated with changes in GABArev and EM 
 
Immature cells with high intracellular Cl- due to low levels of KCC2 exhibit relatively depolarized 
GABA-mediated Cl- reversal potentials (GABArev), driving GABA’s excitatory influence (35, 41, 48, 
62, 63). Increased developmental KCC2 expression decreases Cl- levels and hyperpolarizes 
GABArev, shunting action potentials and inhibiting neuronal activity. This has been well described 
in other brain regions as cells mature (48, 63, 64), as well as in disease and injury models (65, 66). 
However, no such measurements have been effectuated in the developing mPFC.  
 
To assess whether the mPFC GABA switch correlates with GABArev hyperpolarization, we 
performed single-channel recordings of GABA-activated Cl- channels. We observed a progressive 
hyperpolarization of GABArev between P9-P21 in the offspring of both Sham- and WIN-treated 
dams (Figure 2A-C). GABArev decreased between P09-10 and P15-16 and remained decreased at 
P20-21 in Sham-treated offspring, but was unchanged between P09-10 and P15-16 in WIN-
exposed offspring. By P20-21, a significant hyperpolarization of GABArev was observed in WIN-
exposed offspring. Together, these data identify a delayed developmental GABArev 
hyperpolarization in the offspring of WIN- versus Sham-treated dams, correlating with the 
retarded trajectory of GABA’s excitatory-to-inhibitory switch. 
 
To interpret the influence of GABArev on action potential probability, we measured the resting 
membrane potential (EM) at these ages in slices of Sham- and WIN-exposed offspring (Figure 2D). 
EM exhibited a progressive hyperpolarization between P09-10 and P15-16 and remained 
consistent at P20-21 in Sham-treated animals. No change was observed WIN-exposed offspring 
between P09-10 and P15-16. However, at P20-21 EM decreased significantly. Thus, in addition to 
a retarded GABArev, hyperpolarization, the decrease of EM in WIN-exposed offspring was delayed 
compared to Sham-exposed pups. 
 
KCC2 upregulation is delayed in perinatally cannabinoid-exposed pups 
 
The potassium-chloride transporter 5 (KCC2), together with the sodium-potassium-chloride 
transporter (NKCC1), regulates intracellular Cl- concentrations thereby determining the ion’s flow 
during GABA channel opening (54). During early development, KCC2 levels increase while NKCC1 
levels decline (37, 54, 67), decreasing intracellular Cl- resulting in a net Cl- influx and cell 
hyperpolarization. This trajectory thereby mediates GABA’s excitatory to inhibitory transition (34, 
68). To determine whether the delayed GABA “switch” (Figure 1-2) was correlated with 
KCC2/NKCC1 expression changes, Western Blot analyses were performed on mPFC of Sham- or 
WIN-exposed pups at P10, P15 and P21. 
 
We found a significant KCC2 increase between P10 and P15 in the mPFC of Sham-exposed pups 
which remain at P21 (Figure 4A). In support of our working hypothesis, KCC2 levels were 
 
 
 
 
 
 
 
 
unchanged between P10-15 in WIN-exposed pups. By P21, levels of KCC2 in WIN-exposed pups 
significantly increased compared to P10. Interestingly, these levels remain low at P21 compared 
to Sham offspring. Together, these data indicate that at P15, the lack of an apparent mPFC GABA 
switch in WIN-exposed pups is correlated with a failure of KCC2 upregulation. 
 
Levels of NKCC1 remain unchanged in both Sham- and WIN-exposed pup mPFC at all three times 
(Figure 4B). Therefore, the influence of GABA on synaptic transmission appears to be dictated by 
the KCC2/NKCC1 ratio, in line with previous findings (34). Importantly, the NKCC1 antagonist 
bumetanide, a previously investigated pharmacotherapeutic treatment targeting GABAergic 
development in neonatal seizures (69), autism (41) and maternal separation-induced stress (70), 
corrected the delayed GABA switch when delivered to developing offspring (Supplementary 
Figure 2). These data confirm the crucial role of Cl- balance in mediating the developmentl GABA 
transition.  
 
KCC2 mRNA transcriptional upregulation between P10-15 in cannabinoid-exposed pups 
 
To gain mechanistic insight into the delayed KCC2 upregulation in cannabinoid-exposed pups, we 
performed qPCR on brains from WIN- or THC-exposed pups. We found a delayed developmental 
upregulation of KCC2 mRNA following perinatal cannabinoid exposure (Figure 5). Specifically, 
mPFC KCC2 mRNA increased in Sham-, but not WIN-exposed animals between P10-  
15. By P21, mPFC KCC2 mRNA levels were significantly elevated in WIN-exposed offspring 
compared to P15. By P21, no difference in mPFC KCC2 mRNA was found WIN- and Sham-exposed 
offspring. These results support the idea that perinatal cannabinoid exposure attenuates the 
transcription KCC2 trajectory. 
 
Ultrasonic vocalizations are altered in pups perinatally exposed to WIN 
 
Ultrasonic vocalizations (USV) are emitted by pups separated from their mothers and play an 
important role in mother-offspring interactions (71, 72), providing an important measure of 
affect, motivation, and social behavior in pathology models (71, 73, 74). As cannabinoid exposure 
adversely affects perinatal neurodevelopment (6, 7, 75) and altered USV emission has been 
associated with a delayed GABA switch (41) and perinatal THC-exposure (50), we evaluated 
isolation-induced USV in Sham-, WIN- or THC-exposed offspring at P09 and P15 (Figure 5). 
 
 
Although no changes were observed in the number of USV, the mean dominant frequency was 
significantly altered (Figure 5A-B). Pups WIN- or THC-exposed pups presented altered USV mean 
dominant frequency compared to the Sham at both time-points. In line with our previous 
findings, co-administration of the CB1R antagonist AM251 prevented the alteration in mean 
dominant frequency at P09 (data not shown). 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
Developmental consequences of perinatal cannabinoid exposure remain woefully under 
researched despite increasing availability of cannabis and its use during and following pregnancy. 
Here, we identified consequences of cannabinoid exposure in early development by treating 
lactating dams with either a synthetic cannabinoid (WIN) or cannabis’s main psychoactive 
ingredient (THC), followed by electrophysiological and biochemical assessment of GABA 
maturation in the mPFC. We observed a significant delay in GABA maturation associated with 
retarded KCC2 upregulation at both a transcriptional and translational level. We also investigated 
the behavioral consequences of perinatal cannabinoid exposure, as both alterations in GABA 
signaling and perinatal drug exposure have been associated with early life behavioral aberrations 
(41, 50, 76). We found a perturbation of USV calls without alterations in motor behavior.  
 
 
First, our results revealed that GABA exhibits excitatory properties in the mPFC in early 
development before transitioning to inhibition between P10-15, as ascertained by cell-attached 
recordings, in line with the timing of this transition in other regions of the developing rat brain, 
including the hippocampus (37, 41), cerebellum (38) and neocortex (77). This maturational 
trajectory is mediated by a change in GABArev, ascertained by single-channel recordings of GABA-
mediated Cl- currents.    
The present results showed that maternal exposure to cannabinoids retards mPFC GABAergic 
development. WIN- or THC-exposed offspring exhibit a significant delay in the mPFC GABA 
“switch.” By preventing this effect with maternal co-administration of a CB1R antagonist we 
confirm its CB1R-mediation. This was associated with similar delays in the hyperpolarizing 
trajectory of both GABArev and EM, indicating that intracellular Cl- levels and the resulting Cl-
reversal through GABA channels determines developing GABA polarity. Additionally, we observed 
a suppressed trajectory of KCC2 protein and mRNA elevation during this period through Western 
blot and qPCR analyses, in parallel with findings elsewhere (36). As membrane localization of 
KCC2 proteins regulates their Cl- balance contribution (78) and certain GABA-development-
perturbing treatments such as maternal separation may alter membrane KCC2 levels (61), future 
experiments must determine whether KCC2 expression changes are similar in the membrane-
associated portion. 
 
This period has also been identified as a crucial time-point in mPFC GABAergic synapse 
innervation (45), underscoring the relevance of this trajectory with regards to GABA function. We 
found that the delayed “switch” was prevented by administration of the NKCC1 antagonist 
bumetanide, which decreases intracellular Cl- to pups. These findings parallel those of others who 
have treated disorders caused by a delayed GABA “shift” with bumetanide (41, 79, 80). 
Unfortunately, significant problems accompany in vivo use of bumetanide, including ototoxicity, 
preclude its use as a pharmacotherapeutic intervention strategy (81, 82). Thus, examination of 
bumetanide’s effects on behavioral consequences of perinatal cannabinoid exposure were 
unsuccessful (data not shown). 
 
Pups from WIN-treated dams exhibited numerous developmental alterations. First, weight gain 
was retarded in pups from cannabinoid-treated dams (Table 4), consistent with the well- 
 
 
 
 
 
 
 
 
established role of eCB signaling in the milk-suckling reflex (6, 8, 83). Exposure to WIN also 
modified USV call structure, indicated by an increase in the calls’ mean dominant frequency at 
P09 and a decrease at P15. Along with changes in the number and mean frequency of USV, calls’ 
structure is altered with age (84, 85), reflecting an evolution from an instinctive behavior elicited 
by litter separation to social behavior (86). Importantly, at P09, co-administration of the CB1R 
antagonist AM251 prevented this delay, implicating CB1Rs. CB1R activation by exogenous 
cannabinoids in lactating dams or their offspring during critical periods of development has been 
demonstrated to trigger USV alterations in progeny associated with later behavioral impairments 
such as reduced adolescent social interaction and play behavior as well as an anxiogenic-like 
profile (50). Further, an elevated cry frequency spectrum has been identified in the offspring of 
cannabis-using mothers (87).  
 
Considering that altered USV may be a harbinger of cognitive impairments, we tested homing 
behavior in WIN-exposed pups at P10 and P13. Along with intact sensory, olfactory and motor 
capabilities, homing requires associative and discriminative capabilities that allow the infant rat 
to recognize and seek its own nest (88). No changes were observed in WIN-exposed offspring, 
indicating a specific behavioral impairment of altered USV structure that may impair mother-
infant interactions (Supplementary Figure 3).    
Importantly, while the negative impact of CB1R activation on rodents’ maternal behaviour has 
been demonstrated (89, 90) we observed no alterations in maternal nursing during WIN or THC 
administration (Table 3). As USV can be modulated by poor maternal care (86, 91, 92), our finding 
highlights the direct effect of WIN administration on pups’ vocalizations. 
 
Long-term consequences of delayed GABA development are unknown. However, it has been 
associated with developmental disorders such as Fragile X syndrome (40), early life epilepsies  
(93) and autism (41, 94, 95). Additionally, there is precedence for developmental GABA 
alterations resulting from a maternal insult such as immune activation (60) as well as postnatal 
exposure to such drugs as caffeine (96). However, we present here the first data suggesting that 
cannabis exposure delays postnatal GABA development. 
 
GABAergic development has diverse impacts including the regulation of newborn neuron 
integration and titration of glutamatergic signaling (97) and mediation of neuronal proliferation, 
migration and synaptogenesis (35). Developmental GABA disturbances in cortical regions also 
impact glutamatergic transmission, presenting as sensorimotor gating deficits associated with 
schizophrenia-like behavior (98). The perinatal cannabinoid-exposure induced retardation of the 
GABA development therefore likely impacts an array of functions in the mPFC and elsewhere, 
whose consequences later in life remain to be investigated. 
 
Together, our results indicate that perinatal cannabinoid exposure via lactation delays the 
developmental mPFC GABA trajectory. This exhibits as a delayed GABA “switch” caused by slowed 
KCC2 upregulation due to suppressed mRNA levels. Furthermore, the normalization of the GABA 
“switch” by bumetanide treatment of pups confirms the mechanistic role of a KCC2/NKCC1 
imbalance. Further analyses of both electrophysiological function and its molecular 
 
 
 
 
 
 
 
 
underpinnings, as well as behavioral consequences associated with this aberrant development 
may reveal long-term consequences of these early postnatal alterations. 
 
 
Figure legends 
 
Figure 1: Developmental shift from excitation to inhibition by GABA-A receptors in rat medial 
prefrontal cortex slices is delayed by perinatal cannabinoid exposure. Action potentials were 
recorded in cell-attached (I=0) layer 5 pyramidal neurons in standard aCSF. After 10 min of 
baseline recording, picrotoxin (20 μM; GABA-A receptor antagonist, PTX) or isoguvacine (7 μM; 
GABA-A receptor agonist, ISO) was bath-applied. Spiking activity was calculated as an average of 
spikes per minute (10 min baseline) compared to the last 10 min of drug application. A-C: GABA-A 
receptor antagonism is inhibitory in immature P09-P10 mPFC networks in the progeny of Sham-, 
WIN-, or THC-treated dams but excitatory at P15 in Sham-exposed offspring and P21 in WIN- or 
THC-exposed offspring. PTX decreased spike frequency in slices obtained from P09-10 rats (Sham: 
N=8 cells/5 rats, WIN: N=6 cells/4 rats, THC N=7 cells/5 rats). In contrast, PTX increased spike 
frequency in slices obtained from Sham-treated P15-16 rats (N=9 cells/6 rats) while continuing to 
decrease spike frequency in slices obtained from WIN- or THC-exposed rats (WIN: N=5 cells/4 
rats, THC: N=5 cells/4 rats). At P20-21, PTX application increased spike frequency in slices 
obtained from either Sham-, WIN-, or THC-exposed rats (Sham: N=5 cells/4 rats, WIN: N=5 cells/4 
rats, THC: N=4 cells/4 rats). Two-way ANOVA revealed a significant drug/postnatal day interaction 
(F4,35 = 6.479, P=0.0003; * indicates P<0.05 as compared to respective P10 normalized post-drug 
firing rate as determined by Tukey’s post-hoc analysis. Error bars indicate SEM. Example traces 
shown in Supplementary Figure 4. D-F: GABA-A receptor agonism is excitatory in immature P09-
10 mPFC networks in the progeny of Sham-, WIN, or THC-treated dams but inhibitory at P15 in 
Sham-exposed offspring and P21 in WIN- or THC-exposed offspring. ISO increased spike frequency 
in slices obtained from P09-10 rats (Sham: N=9 cells/rats, WIN: N=6 cells/4 rats, THC: N=7 cells/4 
rats). In contrast, ISO application decreased spike frequency in slices obtained from P15-16 pups 
from Sham-treated dams (N=11 cells/7 rats) while it continued to increase spike frequency in 
slices obtained from P15-16 pups from WIN- or THC-treated dams (WIN: N=6 cells/rats, THC: N=6 
cells/4 rats). At P20-21, ISO application decreased spike frequency in slices obtained from the 
offspring of all conditions (Sham: N=6 cells/4 rats, WIN: N=6 cells/4 rats, THC: N=6 cells/4 rats). 
Two-way ANOVA revealed a significant drug/postnatal day interaction (F4,55 = 12.94, P<0.0001; * 
indicates P<0.05 as compared to respective P10 normalized post-drug firing rate as determined 
by Tukey’s post-hoc analysis. Error bars indicate SEM. Example traces shown in Supplementary 
Figure 5-6.  
 
Figure 2: Maturational trajectory of the GABA reversal potential (GABArev) and resting 
membrane potential (EM) are delayed by perinatal cannabinoid exposure. Single-channel 
recordings were conducted in cell-attached layer 5 PFC pyramidal neurons collected from 
offspring of either Sham or WIN-treated dams in standard aCSF. Channel opening magnitudes 
were collected from -100mV to +40mV. GABArev was determined from I-V curves as a reversal 
potential of the Cl- currents through GABA-activated channels. EM was obtained in a whole-cell 
patch-clamp configuration. A,B: Current/voltage plots of GABA-activated Cl- channel magnitudes 
 
 
 
 
 
 
 
across imposed membrane voltages. Traces inset for +40 and -100mV at each time-point. Error 
bars indicate 1pa x 1ms. C: GABArev was found to decrease as a function of postnatal age from 
P09-10 (-24.5 ± 3.9 mV, N=10 cells, 3 rats) to P15-16 (-43.33 ± 2.79 mV, N=6 cells, 3 rats) and 
remained decreased in slices obtained from the offspring of Sham-treated dams at P20-21 (-48.57 
± 2.3 mV, N=7 cells, 3 rats). Conversely, GABArev remained elevated in slices obtained from the 
progeny of WIN- or THC-treated dams between P09-10 (-41.67 ± 4.05 mV, N=12 cells, 3 rats) and 
P15-16 (-40.25 ± 2.49 mV, N=10 cells, 3 rats), but decreased by P20-21 (-60.0 ± 1.82 mV, N=9 
cells, 3 rats). As a result, Sidak’s multiple comparisons test following a significant Two-way 
ANOVA (Treatment, F1,48 = 9.267, P=0.0038) revealed a significant difference at P10 (P=0.0006). 
D: EM progressively decreased as a function of postnatal age in slices obtained from the progeny 
of Sham-treated rats. Between P09-10 and P15-16, EM decreased from -71.79 ±   
0.64 mV to -78.03 ± 0.93 mV (N=5 cells, 3 rats and 6 cells, 3 rats, respectively) and remained 
decreased at P20-21 (-78.31 ± 1.43 mV, 7 cells, 3 rats). Conversely, EM did not change between 
P09-10 and P15-16 in the offspring of WIN-treated dams (-68 ± 1.3 mV and -69.21 ± 1.25 mV, 
respectively; N=7 cells, 3 rats and 10 cells, 3 rats, respectively). However, at P20-21 the EM 
significantly decreased to -76.5 ± 0.99 mV (N=9 cells, 3 rats). As a result, Sidak’s multiple 
comparisons test following a significant Two-way ANOVA (Treatment, F1,39 = 23.25, P<0.0001) 
revealed a significant difference between EM at P15, when a decrease was found in cells of slices 
obtained from the offspring of Sham-, but not WIN-treated dams (P<0.0001). Error bars indicate 
SEM. 
 
Figure 3: Perinatal WIN-exposure alters the developmental trajectory of KCC2 and NKCC1 
expression in the mPFC. Western-blot analysis of KCC2 and NKCC1 reveal altered expression 
levels between P10, P15 and P21 in progeny of dams exposed to WIN during lactation as 
compared to progeny of Sham-treated dams. A: KCC2 levels are significantly increased between 
P10 and P15 and remain elevated at P21 in the mPFC tissue collected from pups of Sham-treated 
dams (P10 N=8, P15 N=8, P21 N=8; F5,42=19.38, P<0.0001. One-way ANOVA followed by Tukey’s 
multiple comparisons test. Sham P10 vs. Sham P15, P<0.0001; Sham P15 vs. Sham P21, P=0.9744). 
However, no change in KCC2 levels was detected in mPFC tissue collected from pups of WIN-
treated dams between P10 and P15 (P10 N=6, P15 N=8). At P21, a significant increase in KCC2 
was observed in mPFC tissue from WIN-treated pups as compared to P10 (P21 N=10; P=0.0009, 
Tukey’s multiple comparisons test). B: No difference in NKCC1 levels was detected in mPFC tissue 
collected from pups of Sham- or WIN-treated dams at any of the tested time points (Sham P10 
N=8, P15 N=8, P21 N=8; WIN P10 N=6, P15 N=8, P21 N=10). One-way ANOVA followed by Tukey’s 
multiple comparisons test, F5,42 = 1.108, p=0.3707. Error bars indicate SEM. *p<0.05. C,D: 
Representative Western-blots of KCC2/GAPDH and NKCC1/GAPDH, corresponding to a,b 
respectively. 
 
Figure 4: Perinatal THC exposure alters the developmental trajectory of KCC2 mRNA. qPCR 
analysis of KCC2 mRNA reveal altered expression levels between P10 and P15 in progeny of dams 
exposed to THC during lactation as compared to progeny of Sham-treated dams. A: Levels of 
KCC2 mRNA are significantly increased between P10 and P15 and remain elevated at P21 in mPFC 
tissue collected from pups of Sham-treated dams (P10 N=17, P15 N=15, P21 N=10). However, no 
change in KCC2 mRNA levels was detected in mPFC tissue collected from pups of 
 
 
 
 
 
 
 
 
WIN-treated dams between P10 and P15 (P10 N=6, P15 N=6). At P21, levels of KCC2 mRNA in the 
mPFC tissue collected from the progeny of WIN-treated dams are significantly elevated compared 
to P15 (P21 N=10). One-way ANOVA followed by Tukey’s multiple comparisons test, F5,58 = 18.10, 
p<0.0001. Error bars indicate SEM. *p<0.05 
 
Figure 5. Mean dominant frequency of ultrasonic vocalization is altered in pups exposed to WIN 
or THC at both P09 and P15. A,C: The number of USV emitted by pups from litters exposed to 
WIN or THC during the lactation period were not altered (P09, F2,104x = 1.101, P=0.3365; P15, 
F2,31 = 1.417, P=0.2576; one-way ANOVA). B,D: However, the mean dominant frequency of USV 
calls made by pups from both WIN- and THC-treated dams was found to be significantly different 
from the offspring of Sham-treated rats at P09 (F3,88 = 6.239, P=0.0007; one-way ANOVA) and at 
P15 (F2,31 = 6.656, P=0.0039; one-way ANOVA). P9: Sham, N=21 pups/5 litters; WIN, N=12 pups/4 
litters and THC, N=19 pups/5 litters. P15, N= 10 pups/2 litters; WIN, N= 14 pups/2 litters and THC 
N=10 pups/2 litters). Scatter dot plot represents one animal. Error bars indicate SEM. *p<0.05. 
   
Table 1: Sex-distribution of electrophysiological data (Picrotoxin; PTX). Samples used in 
electrophysiological data were collected from both male and female rats at all ages. Values for 
individual groups are expressed as individual rats. Mean and SEM are given for post-PTX relative 
(normalized) spike frequency. No significant differences were found between sexes within 
treatment groups responding to PTX in slice conditions. 
 
Table 2: Sex-distribution of electrophysiological data (Isoguavacine; ISO). Samples used in 
electrophysiological data were collected from both male and female rats at all ages. Values for 
individual groups are expressed as individual rats. Mean and SEM are given for post-ISO relative 
(normalized) spike frequency. No significant differences were found between sexes within 
treatment groups responding to ISO in slice conditions. 
 
Table 3: Nursing time did not differ between treatment conditions. Data were collected from 
litters for each condition as described in Methods (Sham N=4, WIN N=4, THC N=4, AM+WIN N=3). 
Values are presented as the percentage of total time during the observation period ± SEM. Total 
time spent nursing (i.e. the combined percentage of “arched”, “blanket” and “passive” nursing as 
compared to the percentage of “no nursing” observations) did not differ between groups 
(F9,44=1.116, P=0.3719. Two-way ANOVA followed by Tukey’s post-hoc analysis). 
 
 
Table 4: Pup weights are significantly reduced during the treatment period by perinatal 
cannabinoid exposure. Pups weights were collected daily from P01-P10 (Sham N=4, WIN N=4, 
THC N=4, AM+WIN N=3). Values are expressed as mean (grams) ± SEM. P values are given for 
each day as compared to pups from Sham-treated dams on the same postnatal day, as 
determined by Tukey’s post-hoc comparison following a significant Two-way ANOVA 
(F27,63=14.68, P<0.0001). 
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Parameter PND Treatment Sex n Mean SEM P value 
(unpaired 
t test)  
PTX 10 Sham Male 5 67.25 9.99 0.9699
  Sham Female 5 67.72 6.62  
  WIN Male 3 77.76 7.40 0.4998
  WIN Female 3 69.22 8.79  
  THC Male 4 53.44 5.32 0.3985
  THC Female 4 46.13 6.024  
  AM+WIN Male 3 23.58 8.226 0.9770
  AM+WIN Female 2 23.03 14.12  
  Bumetanide + WIN Male 3 60.18 12.91 0.8462
  Bumetanide + WIN Female 2 55.64 16.36  
PTX 15 Sham Male 5 158.6 27.65 0.6290
  Sham Female 5 143.5 10.5  
  WIN Male 3 59.53 18.34 0.8815
  WIN Female 2 62.67 3.76  
  THC Male 3 64.36 10.58 0.4957
  THC Female 3 54.60 7.36  
  AM+WIN Male 3 131.3 9.38 0.7676
  AM+WIN Female 3 140.7 27.05  
  Bumetanide + WIN Male 3 171.0 36.38 0.8219
  Bumetanide + WIN Female 3 160.9 19.63  
PTX 20 Sham Male 3 148.9 40.09 0.8878
  Sham Female 2 141.1 31.11  
  WIN Male 3 176.8 46.43 0.9621
  WIN Female 2 180.1 44.85  
  THC Male 3 189.8 50.37 0.7790
  THC Female 3 173.4 12.31  
 
Table 1: Sex-distribution of electrophysiological data (Picrotoxin; PTX). Samples used in 
electrophysiological data were collected from both male and female rats at all ages. Values 
for individual groups are expressed as individual rats. Mean and SEM are given for post-PTX 
relative (normalized) spike frequency. No significant differences were found between sexes 
within treatment groups responding to PTX in slice conditions. 
Parameter PND Treatment Sex n Mean SEM P value 
(unpaired 
t test)  
ISO 10 Sham Male 5 113.0 7.107 0.3383
  Sham Female 4 128.1 12.31  
  WIN Male 3 137.5 22.46 0.5465
  WIN Female 3 121.1 6.488  
  THC Male 4 146.7 10.04 0.9843
  THC Female 3 146.5 6.586  
  AM+WIN Male 3 140.2 3.376 0.6531
  AM+WIN Female 3 170.8 58.41  
  Bumetanide + WIN Male 3 162.2 30.79 0.4224
  Bumetanide + WIN Female 3 194.8 17.69  
ISO 15 Sham Male 5 58.93 7.867 0.9168
  Sham Female 7 61.08 18.02  
  WIN Male 3 130.9 5.228 0.1707
  WIN Female 3 148.6 8.663  
  THC Male 3 162.0 25.94 0.9455
  THC Female 3 159.6 20.41  
  AM+WIN Male 3 49.59 21.73 0.8974
  AM+WIN Female 3 46.01 14.06  
  Bumetanide + WIN Male 4 43.03 13.16 0.8393
  Bumetanide + WIN Female 4 47.76 17.97  
ISO 20 Sham Male 3 57.87 11.38 0.5154
  Sham Female 3 48.45 5.899  
  WIN Male 3 55.22 8.797 0.5470
  WIN Female 3 46.18 10.53  
  THC Male 3 43.04 21.91 0.7646
  THC Female 3 35.42 5.412  
 
Table 2: Sex-distribution of electrophysiological data (Isoguavacine; ISO). Samples used in 
electrophysiological data were collected from both male and female rats at all ages. Values 
for individual groups are expressed as individual rats. Mean and SEM are given for post-ISO 
relative (normalized) spike frequency. No significant differences were found between sexes 
within treatment groups responding to ISO in slice conditions. 
 
Table 3: 
Nursing 
time did 
not differ 
between 
treatment 
conditions. 
Data were 
collected 
from litters for each condition as described in Methods (Sham N=4, WIN N=4, THC N=4, 
AM+WIN N=3). Values are presented as the percentage of total time during the observation 
period ± SEM. Total time spent nursing (i.e. the combined percentage of “arched”, “blanket” 
and “passive” nursing as compared to the percentage of “no nursing” observations) did not 
differ between groups (F9,44=1.116, P=0.3719. Two-way ANOVA followed by Tukey’s post-
hoc analysis).  
Nursing Arched Blanket Passive No nursing Total time 
behavior nursing nursing nursing  in nest 
      
Sham 8.33±3.40 48.96±12.31 26.67±2.55 11.46±3.56 88.54±1.78 
      
WIN 9.37±3.56 58.33±2.95 16.67±8.74 16.67±5.38 89.58±1.80 
      
THC 9.37±3.56 54.17±4.50 19.17±1.99 18.75±2.69 91.67±0.85 
      
AM+WIN 8.33±2.08 43.06±3.18 30.21±6.36 16.67±5.51 94.44±0.60 
      
Postnatal Sham WIN THC AM+WIN 
day     
weights     
P01 8.23±0.24 7.55±0.50 7.11±1.25 7.07±1.96 
  P=0.9480 P=0.7490 P=0.7243 
P02 9.38±0.79 8.39±0.31 7.86±1.02 8.21±1.72 
  P=0.8620 P=0.5293 P=0.7262 
P03 10.82±0.83 9.89±1.53 8.23±0.85 9.48±1.65 
  P=0.8827 P=0.1036 P=0.6320 
P04 12.59±1.48 10.48±0.55 9.23±0.94 11.11±2.06 
  P=0.3400 P=0.0190 P=0.6451 
P05 14.30±2.03 12.05±0.25 10.88±1.14 12.98±2.41 
  P=0.2824 P=0.0190 P=0.5548 
P06 17.28±2.34 13.89±0.38 12.67±1.17 14.87±2.62 
  P=0.0414 P=0.0006 P=0.1453 
P07 20.66±1.55 16.39±0.38 14.31±0.55 17.35±1.59 
  P=0.0057 P=0.0006 P=0.1453 
P08 22.95±0.87 18.11±0.18 15.59±0.42 19.86±1.88 
  P=0.0057 P<0.0001 P=0.0209 
P09 26.64±0.83 20.40±0.69 17.77±0.52 23.53±1.60 
  P<0.0001 P<0.0001 P=0.0346 
P10 29.09±0.85 23.36±0.35 19.47±0.46 26.47±1.68 
  P=0.0001 P<0.0001 P=0.0970 
 
 
Table 4: Pup weights are significantly reduced during the treatment period by perinatal 
cannabinoid exposure. Pups weights were collected daily from P01-P10 (Sham N=4, WIN 
N=4, THC N=4, AM+WIN N=3). Values are expressed as mean (grams) ± SEM. P values are 
given for each day as compared to pups from sham-treated dams on the same postnatal 
day, as determined by Tukey’s post-hoc comparison following a significant Two-way ANOVA 
(F27,63=14.68, P<0.0001). 
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